Gilder Gagnon Howe & Co. LLC trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,088,895 shares of the biopharmaceutical company’s stock after selling 5,821 shares during the quarter. Gilder Gagnon Howe & Co. LLC’s holdings in Alnylam Pharmaceuticals were worth $95,300,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in ALNY. Point72 Asset Management L.P. grew its position in Alnylam Pharmaceuticals by 49.4% during the second quarter. Point72 Asset Management L.P. now owns 1,356,408 shares of the biopharmaceutical company’s stock valued at $133,593,000 after buying an additional 448,362 shares during the period. American Century Companies Inc. bought a new stake in Alnylam Pharmaceuticals during the second quarter valued at approximately $42,128,000. Baillie Gifford & Co. grew its position in Alnylam Pharmaceuticals by 10.4% during the second quarter. Baillie Gifford & Co. now owns 4,231,881 shares of the biopharmaceutical company’s stock valued at $416,798,000 after buying an additional 397,668 shares during the period. First Trust Advisors LP grew its position in Alnylam Pharmaceuticals by 42.0% during the third quarter. First Trust Advisors LP now owns 937,025 shares of the biopharmaceutical company’s stock valued at $82,008,000 after buying an additional 277,259 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. grew its position in Alnylam Pharmaceuticals by 333.0% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 302,695 shares of the biopharmaceutical company’s stock valued at $29,812,000 after buying an additional 232,782 shares during the period. Institutional investors own 90.09% of the company’s stock.

Get Alnylam Pharmaceuticals alerts:

In other news, COO Yvonne Greenstreet sold 2,500 shares of the business’s stock in a transaction on Thursday, August 30th. The shares were sold at an average price of $120.00, for a total value of $300,000.00. Following the transaction, the chief operating officer now owns 1,916 shares of the company’s stock, valued at $229,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.70% of the stock is currently owned by insiders.

NASDAQ:ALNY traded up $3.98 during trading hours on Tuesday, hitting $77.88. 27,176 shares of the stock traded hands, compared to its average volume of 784,070. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.22 and a quick ratio of 13.22. Alnylam Pharmaceuticals, Inc. has a 1 year low of $71.85 and a 1 year high of $153.99. The company has a market capitalization of $7.73 billion, a P/E ratio of -14.40 and a beta of 2.56.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, beating the consensus estimate of ($1.74) by $0.11. Alnylam Pharmaceuticals had a negative net margin of 533.52% and a negative return on equity of 38.09%. The business had revenue of $29.91 million for the quarter, compared to the consensus estimate of $16.96 million. During the same quarter in the previous year, the firm earned ($1.07) earnings per share. The company’s revenue for the quarter was up 87.8% on a year-over-year basis. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -7.28 earnings per share for the current fiscal year.

Several brokerages recently issued reports on ALNY. BidaskClub lowered shares of Alnylam Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 24th. Stifel Nicolaus upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from $95.00 to $125.00 in a research report on Monday, August 6th. BMO Capital Markets lowered their price target on shares of Alnylam Pharmaceuticals from $125.00 to $124.00 and set an “outperform” rating on the stock in a report on Tuesday, October 16th. Jefferies Financial Group reaffirmed a “buy” rating and set a $149.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, August 6th. Finally, Zacks Investment Research downgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 4th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and sixteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $144.17.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.